Innovating Works

K Watch Glucose

Financiado
KWatch Glucose A Wearable Painless Continuous Glucose Monitoring Smartwatch
Most diabetes preventable emergencies, like severe hypoglycaemia (cost of €1535.8/event in Europe), are linked to a poor self- management. Diabetes management relies on blood glucose (BG) monitoring several times a day. Only 20% o... Most diabetes preventable emergencies, like severe hypoglycaemia (cost of €1535.8/event in Europe), are linked to a poor self- management. Diabetes management relies on blood glucose (BG) monitoring several times a day. Only 20% of the 100M people that should monitor their glucose does it periodically and correctly. This is caused, partially, by the inconveniences of available self-monitoring devices: these devices are painful, burdensome, and expensive. We have developed K'Watch Glucose, a minimally invasive glucose self-monitoring system embedded in a smartwatch. Our innovative technology measures glucose levels from extracted interstitial fluid (ISF), without painful blood-sampling and high accuracy (99%). This is possible thanks to SkinTaste®, a patented, calibration-free biosensor array that uses micro-needles (<0.7mm long) to collect and analyze chemical composition of the interstitial fluid. Thanks to its small size, our solution stays invisible to others, enabling monitoring of glucose levels anytime and anywhere, without anyone noticing. In the Accelerator, we will prepare K’Watch Glucose for its successful launch in the European Union and in North America by validating it clinically in our target markets, certifying it as a Class 2 medical device, by pursuing its industrialisation, preparing its reimbursement and establishing a solid commercial network of distributors, insurances and users. K’Watch Glucose could have a significant impact on preventing avoidable hypoglycaemia episode and its associated complications. Considering that we expect to have 830k active users by the end on our 5th commercialization year, K’Watch Glucose could potentially save around €1.27M per year in Europe and $0.96M in US derived just from preventing severe complications led by hypoglycaemia. In 5 years from the Accelerator Program, we estimate a cumulative Profit of €201.1M with a ROI of 10.53, besides a clear social benefit with the recruitment of 139 new employees. ver más
31/10/2023
PKVITALITY
3M€
Duración del proyecto: 36 meses Fecha Inicio: 2020-10-05
Fecha Fin: 2023-10-31

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2023-10-31
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020: SME instrument
Cerrada hace 6 años
Presupuesto El presupuesto total del proyecto asciende a 3M€
Líder del proyecto
PK VITALITY No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5